BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 3463435)

  • 1. Treatment of acute leukaemia with m-AMSA in combination with cytosine arabinoside.
    Dhaliwal HS; Shannon MS; Barnett MJ; Prentice HG; Bragman K; Malpas JS; Lister TA
    Cancer Chemother Pharmacol; 1986; 18(1):59-62. PubMed ID: 3463435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High-dose cytosine arabinoside and amsacrine or mitoxantrone in relapsed and refractory acute myeloid leukaemia: a prospective randomized study.
    Martiat P; Ghilain JM; Ferrant A; Doyen C; Delannoy A; Chatelain C; Bosly A; Michaux JL; Sokal G
    Eur J Haematol; 1990 Sep; 45(3):164-7. PubMed ID: 2226729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Combination of AMSA-high dose cytosine arabinoside in acute leukemia].
    Zittoun R; Rio B; Marie JP; Blanc CM
    Presse Med; 1985 Jun; 14(26):1417-20. PubMed ID: 3161047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
    Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
    Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results of induction and consolidation treatment with intermediate and high-dose cytosine arabinoside and m-Amsa of patients with poor-risk acute myelogenous leukaemia.
    Peters WG; Willemze R; Colly LP
    Eur J Haematol; 1988 Mar; 40(3):198-204. PubMed ID: 3162718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermediate-dose Ara-C/m-AMSA for remission induction and high-dose Ara-C/m-AMSA for intensive consolidation in relapsed and refractory adult acute myelogenous leukemia (AML).
    Jehn U; Heinemann V; Wilmanns W
    Anticancer Res; 1989; 9(1):119-24. PubMed ID: 2705739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphoma.
    Willemze R; Peters WG; van Hennik MB; Fibbe WE; Kootte AM; van Berkel M; Lie R; Rodenburg CJ; Veltkamp JJ
    Scand J Haematol; 1985 Jan; 34(1):83-7. PubMed ID: 3855571
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The selective use of AMSA following high-dose cytarabine in patients with acute myeloid leukaemia in relapse: a Leukemia Intergroup study.
    Larson RA; Day RS; Azarnia N; Bennett JM; Browman G; Goldberg J; Gottlieb A; Grunwald H; Miller K; Raza A
    Br J Haematol; 1992 Oct; 82(2):337-46. PubMed ID: 1419816
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AMSA combination chemotherapy in patients with acute myelogenous leukemia unsuitable for standard antileukemic treatment.
    Maschmeyer G; Willborn K; Heit W
    Leuk Lymphoma; 1992 Nov; 8(4-5):365-9. PubMed ID: 1290961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [4'-(9-acridinylamino)-methanesulfon-m-aniside (AMSA) combination salvage therapy in refractory acute non-lymphocytic leukemia in adults].
    Mukaiyama T; Ogawa M; Horikoshi N; Inoue K; Fukutani H; Tabata M; Hirano A; Mizunuma N; Itami S
    Gan To Kagaku Ryoho; 1989 May; 16(5):2019-23. PubMed ID: 2730091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A new regimen of amsacrine with high-dose cytarabine is safe and effective therapy for acute leukemia.
    Arlin ZA; Ahmed T; Mittelman A; Feldman E; Mehta R; Weinstein P; Rieber E; Sullivan P; Baskind P
    J Clin Oncol; 1987 Mar; 5(3):371-5. PubMed ID: 3546613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Amsacrine and continuous-infusion high-dose cytosine arabinoside as induction therapy for patients with newly-diagnosed acute myelogenous leukemia.
    Ghaddar HM; Pierce S; Kantarjian HM; Freireich EJ; Keating MJ; Estey EH
    Leuk Lymphoma; 1996 Jun; 22(1-2):71-6. PubMed ID: 8724530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose cytosine arabinoside in combination with mitoxantrone for the treatment of refractory acute myeloid and lymphoblastic leukemia.
    Hiddemann W; Kreutzmann H; Straif K; Ludwig WD; Mertelsmann R; Planker M; Donhuijsen-Ant R; Lengfelder E; Arlin Z; Büchner T
    Semin Oncol; 1987 Jun; 14(2 Suppl 1):73-7. PubMed ID: 3473685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive treatment of acute leukemia in adults 70 years of age and older.
    Walters RS; Kantarjian HM; Keating MJ; Estey EH; McCredie KB; Freireich EJ
    Cancer; 1987 Jul; 60(2):149-55. PubMed ID: 3474052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aclarubicin plus cytosine arabinoside versus daunorubicin plus cytosine arabinoside in previously untreated patients with acute myeloid leukemia: a Danish national phase III trial. The Danish Society of Hematology Study Group on AML, Denmark.
    Hansen OP; Pedersen-Bjergaard J; Ellegaard J; Brincker H; Boesen AM; Christensen BE; Drivsholm A; Hippe E; Jans H; Jensen KB
    Leukemia; 1991 Jun; 5(6):510-6. PubMed ID: 2056774
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effective reinduction therapy for childhood acute nonlymphoid leukemia using simultaneous continuous infusions of teniposide and amsacrine.
    Mirro J; Kalwinsky DK; Grier HE; Santana VM; Mason C; Murphy SB; Dahl GV
    Cancer Chemother Pharmacol; 1989; 24(2):123-7. PubMed ID: 2731312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensified double induction therapy with high dose mitoxantrone, etoposide, m-amsacrine and high dose ara-C for elderly acute myeloid leukemia patients aged 61-65 years.
    Schaich M; Illmer T; Aulitzky W; Bodenstein H; Clemens M; Neubauer A; Repp R; Schäkel U; Soucek S; Wandt H; Ehninger G;
    Haematologica; 2002 Aug; 87(8):808-15. PubMed ID: 12161356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I and II study of m-AMSA in acute leukaemia.
    Slevin ML; Shannon MS; Prentice HG; Goldman AJ; Lister TA
    Cancer Chemother Pharmacol; 1981; 6(2):137-40. PubMed ID: 6946878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of AMSA in previously treated patients with acute leukemia: results of therapy in 109 adults.
    Legha SS; Keating MJ; McCredie KB; Bodey GP; Freireich EJ
    Blood; 1982 Aug; 60(2):484-90. PubMed ID: 6953987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adriamycin in the treatment of acute leukaemia.
    Whitehouse JM; Crowther D; Bateman CJ; Beard ME; Malpas JS
    Br Med J; 1972 Feb; 1(5798):482-3. PubMed ID: 4500405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.